- Home
- PTY vs CDTX Comparison
PTY vs CDTX Comparison
Compare PTY & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTY
- CDTX
- Stock Information
- Founded
- PTY 2002
- CDTX 2012
- Country
- PTY United States
- CDTX United States
- Employees
- PTY N/A
- CDTX N/A
- Industry
- PTY Investment Managers
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PTY Finance
- CDTX Health Care
- Exchange
- PTY Nasdaq
- CDTX Nasdaq
- Market Cap
- PTY 2.8B
- CDTX 2.8B
- IPO Year
- PTY N/A
- CDTX 2015
- Fundamental
- Price
- PTY $13.63
- CDTX $100.35
- Analyst Decision
- PTY
- CDTX Strong Buy
- Analyst Count
- PTY 0
- CDTX 13
- Target Price
- PTY N/A
- CDTX $118.50
- AVG Volume (30 Days)
- PTY 550.4K
- CDTX 867.5K
- Earning Date
- PTY 01-01-0001
- CDTX 11-06-2025
- Dividend Yield
- PTY 9.65%
- CDTX N/A
- EPS Growth
- PTY N/A
- CDTX N/A
- EPS
- PTY N/A
- CDTX N/A
- Revenue
- PTY N/A
- CDTX N/A
- Revenue This Year
- PTY N/A
- CDTX N/A
- Revenue Next Year
- PTY N/A
- CDTX N/A
- P/E Ratio
- PTY N/A
- CDTX N/A
- Revenue Growth
- PTY N/A
- CDTX N/A
- 52 Week Low
- PTY $11.92
- CDTX $12.74
- 52 Week High
- PTY $14.88
- CDTX $121.21
- Technical
- Relative Strength Index (RSI)
- PTY 37.63
- CDTX 51.66
- Support Level
- PTY $13.65
- CDTX $95.73
- Resistance Level
- PTY $13.78
- CDTX $113.00
- Average True Range (ATR)
- PTY 0.18
- CDTX 6.30
- MACD
- PTY -0.00
- CDTX -1.59
- Stochastic Oscillator
- PTY 59.79
- CDTX 32.84
About PTY Pimco Corporate & Income Opportunity Fund
PIMCO Corporate & Income Opportunity Fds operates as a closed-end management investment company. It seeks to maximize total return through a combination of current income and capital appreciation. The fund invests a majority of the total assets in a combination of corporate debt obligations of varying maturities, other corporate income-producing securities, and income-producing securities of non-corporate issuers, such as U.S. Government securities, municipal securities, and mortgage-backed and other asset-backed securities issued on a public or private basis.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.